| Zhang, Helong |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT04990063: Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 1 | 20 | RoW | Chemotherapy, Adoptive TKC transfer therapy | suhaichuan, Shanghai Biomed-union Biotechnology Co., Ltd. | Advanced Non-small Cell Lung Cancer, Chemotherapy | 08/22 | 11/23 | | |
| Jin, Faguang |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
| Zhou, Yongan |
NCT04554524: Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma |
|
|
| Recruiting | 4 | 40 | RoW | Chemotherapy+Pembrolizumab., Carbo-paclitaxel/ nab-paclitaxel | Tang-Du Hospital | Thymoma and Thymic Carcinoma | 07/24 | 07/24 | | |
3-Hole, NCT02317224: The Safety and Efficacy of "" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor |
|
|
| Recruiting | 2 | 240 | RoW | "3-Hole" subxiphorid and subcostal approach, 3-Hole approach, Trans sternal approach, median sternotomy, VATS approach, Video-assisted thoracoscope | Tang-Du Hospital | Thymectomy, Myasthenia Gravis | 12/24 | 12/24 | | |
| Su, Haichuan |
NCT06467786: Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer |
|
|
| Recruiting | 4 | 24 | RoW | Irinotecan hydrochloride liposome injection | Tang-Du Hospital | Small Cell Lung Cancer | 09/25 | 09/28 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
TQB3616-ALTN-II-01, NCT04924192: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer |
|
|
| Recruiting | 2 | 126 | RoW | TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Lung Carcinoma | 05/23 | 12/23 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04990063: Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 1 | 20 | RoW | Chemotherapy, Adoptive TKC transfer therapy | suhaichuan, Shanghai Biomed-union Biotechnology Co., Ltd. | Advanced Non-small Cell Lung Cancer, Chemotherapy | 08/22 | 11/23 | | |
NCT05745454: A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors |
|
|
| Not yet recruiting | 1 | 12 | NA | HER2-E-CART cells | su haichuan | Solid Tumor | 12/23 | 12/25 | | |
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT06352502: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis |
|
|
| Recruiting | N/A | 30 | RoW | Furmonertinib, AST2818 | Tang-Du Hospital | EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases | 09/24 | 09/24 | | |
